Glioma
TransMolecular Reports Positive Phase 2 Data from Study of (131)Iodine Radiolabeled TM-601 in Recurrent Glioma
Published in Clinical Trials Week, December 3rd, 2007
TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, announced the presentation of positive Phase 2 interim results for the intracavitary delivery of its anti-cancer compound (131)I-TM-601 in recurrent malignant glioma at the Society for Neuro-Oncology's 12th Annual Scientific Meeting in Dallas, TX. An interim efficacy analysis from the ongoing, open-label Phase 2 safety and efficacy study demonstrated that the overall survival from the time of recurrence for the highest dosing regimen was estimated at 12.1 months, versus 9.0 months for the lowest dose group. Additionally, no dose-limiting toxicities were observed in the dose-escalation phase of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2007-12-03)
More Articles from Clinical Trials Week
- Clinical Trial Research
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study - Combination Therapy
LifeCycle Pharma Completes Patient Enrollment in Phase II Clinical Trial of LCP-AtorFen for the Treatment of Mixed Dyslipidemia, Initiates 52-Week Open Label Extension Study - Gene Therapy
Ability of Neurologix's Gene Transfer Therapy to Quiet Abnormal Brain Activity in Parkinson's Disease Patients Reported in PNAS - Myeloma
The International Myeloma Foundation Says REVLIMID(R) Extends Survival with Positive Implications for a Wide Range of Blood Cancers - Allergies
New allergies study findings recently were published by S. Wenzel and co-researchers - Bladder Cancer
Researchers at University of Toronto target bladder cancer - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
